BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.

Cell Rep 2017 02;18(9):2162-2174

Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia. Electronic address:

BET inhibitors (BETi) target bromodomain-containing proteins and are currently being evaluated as anti-cancer agents. We find that maximal therapeutic effects of BETi in a Myc-driven B cell lymphoma model required an intact host immune system. Genome-wide analysis of the BETi-induced transcriptional response identified the immune checkpoint ligand Cd274 (Pd-l1) as a Myc-independent, BETi target-gene. BETi directly repressed constitutively expressed and interferon-gamma (IFN-γ) induced CD274 expression across different human and mouse tumor cell lines and primary patient samples. Mechanistically, BETi decreased Brd4 occupancy at the Cd274 locus without any change in Myc occupancy, resulting in transcriptional pausing and rapid loss of Cd274 mRNA production. Finally, targeted inhibition of the PD-1/PD-L1 axis by combining anti-PD-1 antibodies and the BETi JQ1 caused synergistic responses in mice bearing Myc-driven lymphomas. Our data uncover an interaction between BETi and the PD-1/PD-L1 immune-checkpoint and provide mechanistic insight into the transcriptional regulation of CD274.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.02.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340981PMC
February 2017
42 Reads

Publication Analysis

Top Keywords

immune checkpoint
8
immune system
8
host immune
8
checkpoint ligand
8
beti
7
cd274
5
patient samples
4
samples mechanistically
4
cell lines
4
primary patient
4
lines primary
4
mechanistically beti
4
brd4 occupancy
4
change myc
4
myc occupancy
4
occupancy transcriptional
4
locus change
4
cd274 locus
4
decreased brd4
4
tumor cell
4

Similar Publications